Cutaneous candidiasis, caused by Candida albicans, is a severe and frustrating condition,
and finding effective treatments can be challenging. Therefore, the development of farnesol …

The present study is envisaged to develop nanoethosomal formulation for enhanced topical
delivery of amphotericin B (AmB) for the treatment of cutaneous fungal infections. AmB …

Objectives The aim of the study was to formulate and characterize the farnesol loaded
niosomes comprising gel formulation and perform their in vitro–in vivo evaluation for …

Aim of this work was to prepare and characterize fluconazole (FLZ) encapsulated
ethosomes, incorporate it in suitable dermatological base, and asses its comparative clinical …

Fungal infections have become a subject of great concern and the incidence of fungal
infections is increasing, presenting an enormous challenge to healthcare professionals …

In this investigation, we focused on ceramide IIIB, a skin component whose depletion tends
to augment multiple skin disorders and fungal infections. Ceramide IIIB was included into …

The evolution of drug resistance of Candida species to conventional antifungal agents has
been a major medical challenge worldwide; attempt to use the potential antifungal agents …

Miconazole nitrate (MCNR), an antifungal drug, is used to treat superficial infections. The
objective of the current study was to assess the antifungal effectiveness of MCNR-loaded …

Farnesol prevents the germination of yeast cells into mycelia, a fact that may be useful in
eliminating C. albicans pathogenicity. Given the clinical potential of farnesol, its impact on C …

The occurrence of topical fungal infections is increasing nowadays. Cutaneous fungal
infections like cutaneous candidiasis are more prominent in patients associated with AIDS …